Evaluate the Efficacy and Safety of Reslizumab for Patients with Eosinophilic Asthma

Study Title
A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
Teva Identifier
C38072/3081 | 2010-023342-67
ClinicalTrials.gov Identifier
NCT01270464
Study Status
Completed
Trial Condition(s)
Eosinophilic Asthma
Interventions
Drug: Reslizumab | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
12 Years to 75 Years
Trial Duration
02/01/2011 - 09/01/2013
Phase
Phase 3

Study Type

Interventional